Marc Whitehead August 2018

Disability

Digest

Aug/Sept 2018 888-497-9061 |DisabilityDenials.com

A T T O R N E Y S A T L A W , L L P

Undisclosed Risks Claims Against Xarelto

is no known antidote. When uncontrolled bleeding occurs, there is no way to quickly and effectively make the blood clot. Even small injuries can be life-threatening for patients taking Xarelto. Making matters worse, it’s likely that the manufacturers and marketers were well-aware of these risks when they brought the product to market. Even in 2014, well after the lawsuits started rolling in, the makers of Xarelto attempted to get the drug approved for the treatment of more conditions. From August 2013 through May 2016, they altered the warning label on the drug five separate times. It’s a matter of great debate in the legal community whether the FDA has the reach and resources to be able to keep massive pharmaceutical companies from bringing less-than-fully-vetted medications to market. There’s no doubt that the regulating body tries their best, but the pressure for an approval is overwhelming. When companies fail to disclose risks to the FDA or patients, it’s the patients who need to demand justice. If you or somebody you know has been injured by taking Xarelto, you can file a tort or civil action claim against the companies responsible. The attorneys at our firm have years of experience dealing with cases like these and can help you get what you’re entitled to. Call us

treatment of deep vein thrombosis (DVT), but its use would later extend to reducing the risk of stroke in many patients. Upon its release, Xarelto received praise for its innovative qualities. Unlike other anticoagulants, Xarelto works effectively with just one daily oral dose. It doesn’t require the regular blood monitoring, dosage adjustments, or dietary restrictions of its competitors. With so many apparent advantages, sales of Xarelto skyrocketed, earning Johnson & Johnson over $400 million in the third quarter of 2014 alone. But there was a serious problem. In their rush to get the product to market and make money, the companies behind Xarelto failed to disclose serious risks to patients. Chief among them was the risk of uncontrolled bleeding, especially in the brain and gastrointestinal system. While this risk is common in medications of its kind, Xarelto poses a specific problem because there

Medicine is advancing all the time, whether through the introduction of new drugs or the development of advanced medical devices. Of course, you can’t just create, market, and sell a medical product like you would a t-shirt or book. The Food and Drug Administration (FDA) rigorously tests all medications and devices before they are allowed to be sold on a wide scale. In an ideal world, an FDA approval would guarantee that all the risks of a product were well-known and patients would understand them. Sadly, the FDA isn’t perfect, and medicine occasionally makes it to market without users being properly warned. Such is the case with Xarelto (Rivaroxaban), which was first approved by the FDA in 2011. Manufactured by Bayer and marketed by Janssen, a division of Johnson & Johnson, Xarelto was touted as a revolutionary anticoagulant and an alternative to drugs like warfarin. The FDA initially approved the drug for use in the

today to see how we can help. -Marc Whitehead

A N ational D isability L aw F irm • SOCIAL SECURITY DISABILITY CLAIMS • LONG-TERM DISABILITY INSURANCE CLAIMS

VETERANS’ DISABILITY BENEFITS

ERISA & EMPLOYEE BENEFIT CLAIMS

• PHARMACEUTICAL & MEDICAL DEVICE LITIGATION

1

Made with FlippingBook - professional solution for displaying marketing and sales documents online